COVID-19 has challenged our industry to quickly rethink and adapt long-standing methods of conducting clinical trials. Important questions have been raised about access to sites and site resourcing, while companies continue to prioritize patient safety, maintain data integrity and reduce the burden on our health care system — all while pivoting to a new virtual trial environment. At Syneos Health, we have developed a staged approach that can help biopharmaceutical companies of all sizes mitigate the effects of COVID-19 on trials.
Reactivating Clinical Trials in a COVID-19 Era
To download the free whitepaper, fill out the form below:
